

(1)

<b>LIST OF REFERENCE(S) CITED</b>				ATTY. DOCKET NO. R0056B-REG		SERIAL NO. 09/450,201	
Corrected Form 1449 - originally filed 4/14/00				APPLICANT(S) DANKWARDT, et al.			
				FILING DATE 10-DEC-1999		GROUP 1653 <del>1048</del>	

10/07/02  
 02/07/02  
 10/07/02  
 10/07/02


U.S. PATENT DOCUMENTS						
Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date

FOREIGN PATENT DOCUMENTS						
	Ref #	Document #	Date	Country; Assignee)	Translation	
					Yes	No
	B-1	ABSTRACT of FR 2762315-A1	22-Apr-1997	France; Laboratoires Logeais SA Jacques  priority for PCT Application WO98/47863, dated Oct 29- 1998		patent in French
	B-2	WO98/22494-A2	28-May-1998	PCT Application; Athena Neurosciences, Inc.	in English	
	B-3	WO97/43251-A1	20-Nov-1997	PCT Application; Italfarmaco S.P.A.	in English	
	B-4	Abstract of WO97/49679-A1	31-Dec-1997	PCT Application; Ono Pharmaceutical Co., Ltd.		patent in Japanese
	B-5	Abstract of WO98/15525-A1	16-Apr-1998	PCT Application; Sumitomo Pharmaceuticals, Co. Ltd.		patent in Japanese
	B-6	EP 0 084941-A1	03-Aug-1983	European Application; Imperial Chemical Industries PLC	in English	
	B-7	Abstract of JP 08311096 A2	26-Nov-1996	Japanese Application; Teijin Ltd.		patent in Japanese

②

LIST OF REFERENCE(S) CITED				ATTY. DOCKET NO. R0056B-REG	SERIAL NO. 09/459,201	
Corrected Form 1449 - Previously mailed to Patent Office on June 26, 2000  Supplemental IDS				APPLICANT(S) DANKWARDT, et al.		
				FILING DATE 10-DEC-1999	GROUP 1653 <del>628</del>	
U.S. PATENT DOCUMENTS						
Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date
FOREIGN PATENT DOCUMENTS						
	Ref. #	Document #	Date	Country; Assignee	Translation	
					Yes	No
DR	B-8	WO 95/12612	11-May-1995	PCT Application; Warner Lambert Company	in English	
I	B-9	WO 92/22523	23-Dec-1992	PCT Application; Research Corporation Technologies, Inc.	in English	
I	B-10	WO 96/33176	24-Oct-1996	PCT Application; The Du Pont Merck Pharmaceutical Co.	in English	
I	B-11	WO 98/55449	10-Dec-1998	PCT Application; The University of Queensland	in English	
↓	B-12	Derwent Abstract of JP 09 025293	28-Jan-1997	Japan; Teijin Ltd.		patent in Japanese
DR	B-13	Derwent Abstract of JP 01 146896	08-Jun-1989	Japan; Fuji Yakuhin Kogyo KK		patent in Japanese
EXAMINER <i>David Little</i>				DATE CONSIDERED 9-8-04		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

3

<b>LIST OF REFERENCE(S) CITED</b>  Supplemental IDS filed 4/4/01				ATTY. DOCKET NO. R0056B-REG		SERIAL NO. 09/458,281	
				APPLICANT(S) DANKWARDT, et al.			
				FILING DATE 10-DEC-1999		GROUP 1646	
<b>U.S. PATENT DOCUMENTS</b>							
Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date	
<b>FOREIGN PATENT DOCUMENTS</b>							
	Ref.#	Document #	Date	Country; Assignee	Translation		
					Yes	No	
DR	B-13	WO 97/05865	20-Feb-1997	PCT Application; Fibrogen	in English		
X	<del>B-14</del>	<del>JP 09 025293</del>	<del>28-Jan-1997</del>	<del>Japanese Patent, Teijin Ltd</del>	No	Japanese	
DL	B-15	CAS abstract and list of compounds to JP 09 025293	28-Jan-1997	Teijin, Ltd	in English		
<b>OTHER DOCUMENTS</b>							
DL	C-7	Fertala, et al., J. Bio. Chem. Vol. 269, pp 11584-11589 (1994), Self-assembly into Fibrils of Collagen II by Enzymic Cleavage of Recombinant Collagen II.					
EXAMINER  				DATE CONSIDERED  9/8/09			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

1999 U.S. PTO  
10/072730

02/07/02

LIST OF REFERENCE(S) CITED		ATTY. DOCKET NO. R0056B-REG	SERIAL NO. 09/459,201
		APPLICANT(S) DANKWARDT, et al.	
		FILING DATE 10-DEC-1999	GROUP 1646
OTHER DOCUMENTS			
	C-1	Ewenson, et al., <u>Eur. J. Med. Chem.</u> Vol. 27:3, pp 179-186 (1992), "Synthesis and biological activity of peptide hydroxamate inhibitors of degradation of substance P analogues"	
	C-2	Chen, et al., <u>Bioorg. Med. Chem. Lett.</u> , Vol. 2:12, pp1685-90 (1992), "One-pot synthesis of cathepsin inhibitors: N $\alpha$ -protected N-peptidyl-o-acetyl hydroxylamines catalysed by alcalase followed by lipase in anhydrous t-butanol"	
	C-3	Nikam, et al., <u>Tetrahedron Letters</u> , Vol. 36:2, pp 197-200 (1995), "Synthesis of hydroxamic acids: Pd/BaSO <sub>4</sub> as a new catalyst for the deprotection of o-benzyl hydroxamates"	
	C-4	Laufer, et al., <u>Eur. Journal of Biochemistry</u> , Vol. 150:1 pp 135-140 (1985), "Inhibition of substance P degradation in rat brain preparations by peptide hydroxamic acids"	
	C-5	Fischer, et al., <u>Pharmazie</u> , Vol. 38:4, pp 249-250 (1983), "N,O-Diacylhydroxylamines as Enzyme-Activated Inhibitors for Serine Proteases"	
	C-6	Hoffmann, et al., <u>Journal of Organic Chemistry</u> , Vol. 29: pp 748-751 (1964), "A Peptide Synthesis via Hydroxamic Acids"	
EXAMINER 		DATE CONSIDERED 9-8-04	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			